Skip to main content

Call for Papers: Clinical Epigenetics of Heart Failure

We are proud to announce a new Collection of articles that aims to address heart failure and epigenetics topics; edited by Giuseppe Paolisso, Ronan Murphy and Marc Vanderheyden. This Collection will gladly consider Original Research, Short Communications, Mini-reviews, and Reviews. Read more about the scope here.

CLEPIC

CLEPIC LogoSave the Date for 

Clinical Epigenetics International Conference - CLEPIC 2024
Warsaw Poland, June 05 – 07, 2024
 

More information at  https://www.clepic.org/

Welcoming words from Lucia Altucci and Marianne Rots, Editors in Chief of Clinical Epigenetics:

The need to meet and greet

Scientists need to meet to stay up-to-date within and beyond one’s own research field, to exchange and fuel new ideas, to keep inspired and to inspire others. Corona-volente, we aim to offer you such platform by bringing together the editors, authors and readers of Clinical Epigenetics as well as the newly launched Epigenetics Communications. Moreover, we will invite industrial partners and public bodies, with a focus on training the next generation of multidisciplinary multi-epiomics scientists. This conference starts a series of annual conferences devoted to fully exploiting the many applications of epigenetics in health and disease as well as in all kingdoms of life (biotech, crop breeding, etc.).

Looking forward to meeting and greeting many of you in a relaxed atmosphere full of state-of-the-art epigenetics!

New thematic series: Multiscale chromatin dynamics

New Content ItemWe are proud to announce a new cross-journal thematic series between Clinical Epigenetics and Epigenetics Communications, guest edited by Wim Vanden Berghe and Pernette Verschure. The last few years have seen a wealth of knowledge on the role of epigenetic gene regulation in (patho-)physiological processes. New insights relate to the highly dynamic nature of epigenetic systems. Epigenetic regulatory proteins are in constant motion in the nucleus, exchanging between chromatin-bound and unbound states. In addition,  various layers of chromatin folding show defined dynamics. The causal relationship between these dynamics of chromatin and nuclear organization with gene activity and silencing is still an open question of great importance. Find out more about the scope here.

New thematic series: Epigenetic Biomarkers

New Content ItemWe are proud to announce a new thematic series, guest edited by Dawn DeMeo, James Flanagan, Harold Snieder, and Tomasz K. Wojdacz. We discuss current progress in development of epigenetic biomarkers for clinical use in common complex diseases of aging and welcome both original research and reviews. The sections of the collection include types of epigenetic biomarkers and readiness for IVD use, progress towards clinical use of biomarkers, single versus multiple biomarkers and risk scores, major stages of clinical validation of the biomarker, biomarker detection technologies suitable for IVD use and significance of bioinformatics, and ethics and regulatory aspects of IVD epigenetic biomarkers. Find out more about the scope here.

Find Best-Fit Journal for your article!

Choosing the right journal is essential for every author, and we are fully committed to collaborating across our prestigious epigenetics journals to assist you in this process. To facilitate an informed decision, we offer a concise overview of our three journals. For more detailed information on each one, simply click on the journal title below: Best fit journal

Clinical Epigenetics

Epigenetics & Chromatin 

Epigenetics Communications

Our dedicated Editors, with their extensive expertise in the field, will carefully evaluate your submission. If they believe that another journal within our network may better align with your research, they will propose a transfer during the peer-review process. This transfer will significantly expedite the handling of your submission, eliminating the need for additional peer-review rounds. We value your research and are here to support you every step of the way. Explore our options and make the most of our collaborative efforts to ensure your work reaches its full potential. 

New Content Item

EACR conference: Cancer Genomics, Multiomics, and Computational Biology

Discover the latest exciting developments in machine learning and artificial intelligence, single cell and spatial analysis of cancers and genomic instability at Cancer Genomics, Multiomics and Computational Biology meeting, held in Bergamo from  30 April to 02 May 2024

Announcing the launch of "Epigenetics Communications"!

New Content ItemWe are pleased to announce the launch of a companion journal to Clinical Epigenetics: Epigenetics Communications! Encompassing the broad spectrum of epigenetics research from basic research to innovations towards therapeutic treatments, Epigenetics Communications is an innovative new, open-access journal devoted to the study of epigenetic principles and mechanisms in basic research settings (without requiring a clinical application). This journal will support the publication of manuscripts that contribute to a further understanding of epigenetic mechanisms that impact functioning of systems and organisms. It will also act as a forum to showcase and discuss alternative conclusions/interpretations of well-established epigenetic phenomena based on (re-)analyses of published or new data. As such, we welcome 'systematic studies', be it positive (expected) or negative (non-expected) with respect to its outcome. Find out more here.

Articles

2023
Clinical Epigenetics of Heart Failure
Edited by Giuseppe Paolisso, Ronan Murphy and Marc Vanderheyden

2022
Cross-journal collection
Alternative Medicine and Epigenetics
Edited by Andy T. Y. Lau and Amy Yan-Ming Xu

Communications in Epigenetics: state of the art and beyond in chromatin biology and pathophysiology
Edited by Renata Z. Jurkowska, Frank Johannes and Tomasz K. Wojdacz

Multiscale chromatin dynamics
Edited by Pernette Verschure and Wim Vanden Berghe

Biomarkers in Clinical Epigenetics
Edited by: Dawn L. DeMeo, James M Flanagan, Harold Snieder, Bea Wisman and Tomasz K Wojdacz

Regenerative Medicine and Epigenetics
First published: 19 January 2021
Edited by: Adele Murrell and Peter Rugg-Gunn

Clinical Epigenetics of COVID-19
First published: 5 August 2020
Edited by: Georges Herbein

2019
Pollution and Epigenetics
First published: 21 January 2019
Edited by: Steven Gray and Wim Vanden Berghe

2018
Cross-journal collection
Pluripotent Stem Cells
First published: 19 July 2018

Cross-journal collection
Asthma Genetics and Epigenetics
Collection first published: 19 October 2016

Epigenetic Drugs
Edited by: Lucia Altucci & Marianne Rots
First published: 23 May 2016

2015
Breakthroughs in clinical epigenetics
Edited by: Marianne Rots
First published: 1 March 2015


Graphical Abstracts Now Available

Authors submitting to Clinical Epigenetics now have the option to include a Graphical Abstract when they submit their manuscript.  An image may be uploaded during submission which, together with the article title and abstract text, should provide the reader with a visual description of the topic covered in the article. Graphical abstracts will appear in the HTML version of the article (but not in the PDF version). Instructions for including graphical abstracts is available in the Submission Guidelines for the appropriate article types.

Editors-in-Chief

Lucia AltucciUniversità degli Studi della Campania, Italy
Marianne RotsUniversity Medical Center Groningen, Netherlands  

Aims & Scope

Encompassing the broad spectrum of epigenetics research from basic research to innovations in therapeutic treatments, Clinical Epigenetics is a top tier, open access journal devoted to the study of epigenetic principles and mechanisms as applied to human development, disease, diagnosis and treatment. The journal particularly welcomes submissions involving clinical trials, translational research, new and innovative methodologies and model organisms providing mechanistic insights. The journal is divided into the following sections:

  • Aging and development epigenetics
  • Allergy, immunology, and pathogen epigenetics
  • Cancer epigenetics and diagnostics
  • Cardiovascular epigenetics
  • Endocrinology and metabolic epigenetics
  • Environmental epigenetics
  • Epigenetic biomarkers
  • Epigenetic technologies
  • Epigenetic Drugs, Trials and Therapy
  • Innovative therapies
  • Lifestyle epigenetics
  • Neurology and psychiatry epigenetics
  • Regenerative medicine
  • Reproductive and transgenerational epigenetics

For more information on the section aims and scope visit our section information page. If you are unclear which section would be best suited to your submission, we invite you to submit a pre-submission inquiry by selecting the Contact Us option here.

Editorial Policy Regarding Submissions Focusing on Non-coding RNAs or RNA Modifications

Manuscripts focusing on differential RNA expression levels (coding or non-coding) or on RNA modifications cannot be considered for publication in Clinical Epigenetics since these aspects are not part of epigenetics per se.

In general, non-coding RNAs affect their target genes at the RNA level, which classifies these molecules as post-transcriptional gene expression regulators. The chromatin effects induced by some ncRNA do not yet justify this, to be included as a general mechanism of action of non-coding RNAs. Similarly, although modifications of RNA molecules resemble modifications of DNA or histone proteins, so do post-translational modifications of non-chromatin proteins. As such, RNA modifications are a novel class of markers, but they are not different from general posttranslational protein modifications (which also are not considered part of epigenetics).

For manuscripts on non-coding RNAs or RNA modifications to be considered for publication in Clinical Epigenetics, the authors must provide at least one of the following:

  • data on the molecular epigenetic regulation of the expression of non-coding RNA (or its modifying enzymes); or
  • insights on the mechanism of action of the non-coding RNA on the chromatin and/or functioning of the DNA; or
  • insights in mitotic stability of the RNA-induced effect.

Editorial Policy Regarding Submissions Focusing on In silico research

Manuscripts reporting on straightforward bioinformatic analyses of publicly accessible databases only, cannot be considered for publication in Clinical Epigenetics, unless the manuscript presents:

  • new insights with well-described strong clinical impact and/or
  • additional insights into biological mechanisms (“wet-lab” validations) and/or
  • validations of findings in a replication cohort.

Archival Content

In October 2011, Clinical Epigenetics became a fully open access journal and is now published as part of BioMed Central's portfolio of journals. To view the journal's content prior to this transition, please see SpringerLink.

Annual Journal Metrics

  • 2022 Citation Impact
    5.7 - 2-year Impact Factor
    6.7 - 5-year Impact Factor
    1.340 - SNIP (Source Normalized Impact per Paper)
    2.014 - SJR (SCImago Journal Rank)

    2023 Speed
    11 days submission to first editorial decision for all manuscripts (Median)
    110 days submission to accept (Median)

    2023 Usage 
    1,435,876 downloads
    3,237 Altmetric mentions